US20140105985A1

US20140105985A1 - Topical use of levofloxacin for reducing lung inflammation

Info

Publication number: US20140105985A1
Application number: US14/134,348
Authority: US
Inventors: Michael N. Dudley; Ruslan Y. Tsivkovski; David C. Griffith; Olga Rodny
Original assignee: Mpex Pharmaceuticals Inc
Current assignee: Horizon Orphan LLC
Priority date: 2008-10-07
Filing date: 2013-12-19
Publication date: 2014-04-17
Also published as: IL212189A0; PL2346509T3; JP2017025106A; DK2346509T3; ES2809177T3; WO2010042549A1; CN102325532B; EP2346509A1; CA2739893A1; CN102325532A; EP2346509B1; HUE050147T2; JP2014159461A; HRP20201150T1; US20180085462A1; US11020481B2; JP2015044825A; US20220080047A1; HRP20201150T8; US20100087386A1

Abstract

The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Ser. No. 12/574,666 entitled “TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION” filed on Oct. 6, 2009 which claims priority to U.S. Provisional Application No. 61/103,496, entitled “Topical Use of Levofloxacin for Reducing Lung Inflammation,” filed on Oct. 7, 2008, which are hereby incorporated by reference in their entireties.

FIELD OF THE INVENTION

BACKGROUND

Inflammation is a response of vascularized tissue to injury; it is perceived as redness, heat, swelling, and pain and is usually accompanied by loss of function to varying degrees. In its acute form it is of short duration, involving increased vascular transudation and interstitial edema and infiltration of inflammatory cells, predominantly of neutrophils. In moist mucosal tissues, such as that which lines the respiratory tract, there may also be loss of surface epithelial cells and secretion of mucus. This form of inflammatory response is considered protective and is, therefore, in the short term, beneficial to the host. However, if the injury is repeated or severe, the character of the inflammatory infiltrate may change to one predominantly of mononuclear cell (i.e., lymphocytes, monocytes, and macrophages) and it may become persistent.
Inflammatory diseases afflict millions of people across the world leading to suffering, economic loss and premature death. As well as inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), other inflammatory diseases include allergic rhinitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and psoriasis. Inflammatory sinus diseases include sinusitis due to infections of acute, subacute and chronic duration; allergic rhinitis; and inflammation due to other underlying causes such as allergies, hay fever, allergic rhinitis, rhinitis, and asthma, affecting the nasal cavity or the four sinuses, each which have left and right halves, the frontal sinuses, the maxillary sinuses the ethmoid sinuses, and the sphenoid sinuses.
Chronic inflammation may develop from unresolved symptomatic acute inflammation or may evolve insidiously over a period of months without apparent acute onset of clinical manifestations. Histopathologic features of chronic inflammation include the predominance of macrophages and lymphocytes, proliferation of nurturing structurally heterogeneous and hyperpermeable small blood vessels, fibrosis, and necrosis. Activated macrophages and lymphocytes are interactive in releasing inflammatory mediators or cytokines that amplify immune reactivity. Cytokines include a family of biologic response modifiers including interleukins, chemokines, interferons, growth factors, and leukocyte colony-stimulating factors. The cytokines are secreted by leukocytes, connective tissue cells, and endothelial cells. Chemokines consist of 8- to 10-kd proteins that stimulate leukocyte recruitment and migration as part of the host response to antigenic insults. In chronic inflammation, the protracted inflammatory response is often accompanied simultaneously by tissue destruction and repair.

SUMMARY

The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
Some embodiments include methods for treating a pulmonary inflammation in a subject in which the methods include administering to the subject in need thereof an aerosol of a solution including levofloxacin or ofloxacin and a divalent or trivalent cation.
Some embodiments include methods for treating a pulmonary inflammation in a subject, wherein the pulmonary inflammation is induced by one or more pro-inflammatory cytokines, in which the methods include administering to the subject in need thereof an aerosol of a solution including levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of said cytokine by at least 10%.
Some embodiments include methods for treating a pulmonary inflammation in a subject in which the methods include administering to the subject in need thereof an aerosol of a solution including levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of one or more pro-inflammatory cytokines including IL-1β, IL-6 and IL-8, whereby the pulmonary inflammation is reduced or suppressed.
Some embodiments include methods for treating a pulmonary inflammation in a subject, wherein the pulmonary inflammation is induced by one or more mediators including TNFα and LPS, in which the methods include administering to the subject in need thereof an aerosol of a solution including levofloxacin or ofloxacin and a divalent or trivalent cation.
Some embodiments include methods for reducing the pulmonary concentration of a pro-inflammatory cytokine in a subject, in which the methods include administering to the subject in need thereof an aerosol of a solution including levofloxacin or ofloxacin and a divalent or trivalent cation, whereby the pulmonary concentration of the cytokine is reduced.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a graph of IL-6 levels produced by NL20 cells in response to treatment with control, TNFα, and TNFα with levofloxacin, moxifloxacin, or ciprofloxacin. FIG. 1B shows a graph of IL-8 produced by NL20 cells in response to treatment with control, TNFα, and TNFα with levofloxacin, moxifloxacin, or ciprofloxacin.

FIG. 2A shows a graph of IL-6 levels produced by HBE135 cells in response to treatment with control, LPS, and LPS with levofloxacin, moxifloxacin, or ciprofloxacin. FIG. 2B shows a graph of IL-8 produced by HBE135 cells in response to treatment with control, LPS, and LPS with levofloxacin, moxifloxacin, or ciprofloxacin.

FIG. 3A shows a graph of percentage cell survival for NL20 cells treated with increasing concentrations of levofloxacin, moxifloxacin, or ciprofloxacin. FIG. 3B shows a graph of percentage cell survival for HBE135 cells treated with increasing concentrations of levofloxacin, moxifloxacin, or ciprofloxacin.

FIG. 4A shows a graph of relative IL-6 levels produced by NL20 cells treated with TNF-α in response to increasing concentrations of levofloxacin and levofloxacin formulated with MgCl₂. FIG. 4B shows a graph of relative IL-8 levels produced by NL20 cells treated with TNF-α in response to increasing concentrations of levofloxacin and levofloxacin formulated with MgCl₂. FIG. 4C shows a graph of relative IL-6 levels produced by HBE135 cells treated with LPS in response to increasing concentrations of levofloxacin and levofloxacin formulated with MgCl₂. FIG. 4D shows a graph of relative IL-8 levels produced by HBE cells treated with LPS in response to increasing concentrations of levofloxacin and levofloxacin formulated with MgCl₂.

FIG. 5A shows a graph of IL-6 levels produced by NL20 cells in response to treatment with control, TNF-α, and TNF-α with 10 μg/ml, 30 μg/ml, 100 μg/ml, or 300 μg/ml levofloxacin or tobramycin. FIG. 5B shows a graph of IL-8 levels produced by NL20 cells in response to treatment with control, TNFα, and TNFα with 10 μg/ml, 30 μg/ml, 100 μg/ml, or 300 μg/ml levofloxacin or tobramycin. Results are means±SD of three replicates. *P<0.005.

FIG. 6 shows a graph of IL-6 and IL-8 levels produced by HBE135 cells in response to treatment with LPS, and LPS with increasing concentrations of levofloxacin or tobramycin. IL-6 and IL-8 levels are shown relative to cells treated with LPS only (n=3). *P<0.05, cells treated with LPS and antibiotics compared to LPS only. **P<0.005, cells treated with LPS and antibiotics compared to LPS only.

FIG. 7A shows a graph of IL-1β levels in THP-1 cells treated with control; LPS; and 10 μg/ml, 30 μg/ml, 100 μg/ml, 300 μg/ml levofloxacin and LPS. FIG. 7B shows a graph of TNFα levels in THP-1 cells treated with control; LPS; and 10 μg/ml, 30 μg/ml, 100 μg/ml, 300 μg/ml levofloxacin and LPS. FIG. 7C shows a graph of IL-6 levels in THP-1 cells treated with control; LPS; and 10 μg/ml, 30 μg/ml, 100 μg/ml, 300 μg/ml levofloxacin and LPS. FIG. 7D shows a graph of IL-8 levels in THP-1 cells treated with control; LPS; and 10 μg/ml, 30 μg/ml, 100 μg/ml, 300 μg/ml levofloxacin and LPS. Cells were incubated with LPS alone or LPS with levofloxacin for 24 h. Cytokine concentration in cell media was determined by ELISA. The results were expressed as mean±SD (n=3). *P<0.05, cells treated with LPS and antibiotics compared to LPS only. **P<0.005, for cells treated with LPS and antibiotics compared to LPS only.

FIG. 8 shows a graph of the relative level of IL-8 mRNA in NL20 cells stimulated with control; TNFα; TNFα and 100 μg/ml levofloxacin; and TNFα and 100 μg/ml levofloxacin. Cells were seeded, serum-starved for 24 h and TNFα alone or TNFα with antibiotic were added and incubated for 24 h. Levels of mRNA were measured by real-time PCR. The results were expressed as means±SD of four replicates.

FIG. 9 shows shows a graph of the relative luciferase activity of a NFkB promoter construct in NL20 cells stimulated with control; TNFα; TNFα and 100 μg/ml levofloxacin; and TNFα and 100 μg/ml levofloxacin. Cells were transfected with the reporter plasmid, and after 24 h treated with TNFα alone or TNFα with antibiotics, then incubated for an additional 8 h. NFkB-dependent luciferase activity was measured using a commercial assay. The results were expressed as means±SD of six replicates.

FIG. 10A shows a graph of MIP-2 levels in BAL of mice treated with 60 mg/kg saline, 60 mg/kg levofloxacin formulated with MgCl₂, or 60 mg/kg tobramycin. FIG. 10B shows a graph of IL-6 levels in BAL of mice treated with 60 mg/kg saline, 60 mg/kg levofloxacin formulated with MgCl₂, or 60 mg/kg tobramycin.

DETAILED DESCRIPTION

The present invention relates to methods and compositions for the treatment of disorders and diseases associated with pulmonary inflammation. In particular, methods and compositions to reduce inflammation using aerosol levofloxacin or ofloxacin formulated with a divalent or trivalent cation are provided. Some embodiments include treating acute or chronic inflammation of the lung or the upper airway by topically administering aerosol levofloxacin or ofloxacin formulated with a divalent or trivalent cation directly to the inflammation site.
Damage to the lungs and subsequent decline in pulmonary function that occurs in chronic inflammation is mediated primarily by neutrophil tissue infiltration that induces subsequent damage through the release of various hydrolytic and oxidative enzymes. This inflammatory cascade at the mucosal surface is mediated by bacteria producing lipopolysacchararide (LPS), and the LPS inducing TNFα release from macrophages or directly at the lung epithelial surface. Release of both TNFα, as well as inflammatory cytokines, for example IL-8 and IL-6, results in neutrophil activation and chemotaxis. While bacterial infections plays a large role in the inflammatory process, it is also believed that impaired chloride secretion in cystic fibrosis or other diseases is also partially responsible for increased cytokine levels (Perez A. et al, Am J. Physiol. Lung Cell Mol Physiol (2007) 292:383-395, incorporated by reference in its entirety).
It has been discovered that topical administration of levofloxacin formulated with divalent or trivalent cations can significantly decrease the level of cytokine and chemokine production in vitro and in vivo. Such decreases in the levels of pro-inflammatory cytokines may produce a reduction in neutrophil-mediated inflammations. Examples of pro-inflammatory cytokines include IL-1, IL-6, IL-7, and IL-8. High concentrations of levofloxacin can be administered to the lungs and upper airways by inhalation. Surprisingly, formulations of levofloxacin with divalent or trivalent cations have greater availability in the lungs compared to formulations of levofloxacin only. Accordingly, the present invention relates to methods and compositions for reducing inflammation in the lungs and upper airway by administration of aerosolized fluoroquinolones, such as levofloxacin, formulated with divalent or trivalent cations, such as Mg²⁺.
Therapeutic approaches for decreasing chronic inflammation are a viable strategy to improve lung function in CF and COPD patients. Anti-inflammatory properties of non-steroidal anti-inflammatory drugs (NSAID) (e.g., ibuprofen) and azithromycin have been associated with benefits in certain CF patient subgroups (Flume P A, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969, incorporated by reference in its entirety). In addition, the antibiotic erythromycin reduces the incidence of pulmonary exacerbations in COPD patients (Seemungal T A, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147, incorporated by reference in its entirety). The efficacy of azithromycin and erythromycin in these settings are likely due in large part to immunomodulatory and anti-inflammatory effects rather than antibacterial effects.
Some fluoroquinolones may have an immunomodulatory activity as well as an anti-bacterial activity. These activities may be distinct and only apparent in vivo at concentrations that are also cytotoxic. Some fluoroquinolones may affect their immunomodulatory activity through various signaling pathways that relate to the production and secretion of various cytokines and chemokines. However, not all fluoroquinolones show immunomodulatory activity. Moreover, different fluoroquinolones illicit different responses, such as the induction or inhibition of particular cytokines and chemokines. The immunomodulatory activity may also depend on cell type, immune stimulant, and concentration of the fluoroquinolone. For example, fluoroquinolones such as moxifloxacin and grepafloxacin, but not ciprofloxacin, can inhibit secretion of pro-inflammatory factor such as IL-8, IL-6, ERK1/2, MK, and NFκB in human lung epithelia cells (Blau, H., K. et al. 2007. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, MK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 292:L343-52; Donnarumma, G., I. et al. 2007. Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide. Peptides 28:2286-92; Hashimoto, S., K. et al. 2000. Grepafloxacin inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in human airway epithelial cells. Life Sci 66:PL 77-82, incorporated by reference in their entireties). However, in all studies cells were treated with antibiotic concentrations less than 50 μg/ml, which corresponds to serum drug concentrations that may be attained after systemic dosing.
Levofloxacin inhibits TNF-α and IFNγ production in tonsillar lymphocytes at 50 mg/L, and IL-8 production at 5 mg/L. In addition, levofloxacin inhibits RANTES-release in nasal epithelial cells from patients of nasal polyposis. However, the inhibitory activity of levofloxacin on the production of pro-inflammatory factors is much lower than that for other fluoroquinolones such as ciprofloxacin and moxifloxacin. For example, the inhibitory activity of levofloxacin on the production of pro-inflammatory factors such as TNF-α, IL-1 and IL-8 requires 100 mg/L levofloxacin.
As described herein, immortalized human airway epithelia cells retain certain features of airway epithelium and have been extensively used to characterize immunomodulatory effects of other antibiotics (Blau H, et al. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, MK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 2007; 292:L343-352; and Donnarumma G, et al. Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide. Peptides 2007; 28:2286-2292, incorporated by reference in their entireties). IL-6 and IL-8 production in those cells can be strongly induced by TNFα or by bacterial LPS that is present in high concentrations in lung fluids of CF and COPD patients (Sagel S D, et al. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007; 4:406-417, incorporated by reference in its entirety). Both IL-6 and IL-8 are of high importance in regulating inflammatory response in CF lungs, with latter having the strongest potential to induce neutrophil chemotaxis (Strieter R M. Interleukin-8: a very important chemokine of the human airway epithelium. Am J Physiol Lung Cell Mol Physiol 2002; 283:L688-689, incorporated by reference in its entirety). It has been discovered that levofloxacin produces a dose-dependent reduction of TNFα- and LPS-induced IL-6 and IL-8 levels in cultured human airway epithelia cells. Levofloxacin also decreases LPS-induced IL-1β, IL-6 and IL-8 production in human monocytic cells. In addition, levofloxacin reduces IL-6 and IL-8 production in vivo.

Definitions

The term “administration” or “administering” refers to a method of giving a dosage of an anti-inflammatory pharmaceutical composition to a vertebrate. The preferred method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the inflammation, and the severity of an actual inflammation.
A “carrier” or “excipient” is a compound or material used to facilitate administration of the compound, for example, to increase the solubility of the compound. Solid carriers include, e.g., starch, lactose, dicalcium phosphate, sucrose, and kaolin. Liquid carriers include, e.g., sterile water, saline, buffers, non-ionic surfactants, and edible oils such as oil, peanut and sesame oils. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, incorporated by reference herein in its entirety.
The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, dogs, and cats, but also includes many other species.
The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which are not biologically or otherwise undesirable. In many cases, the compounds of this invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, naphtoic acid, oleic acid, palmitic acid, pamoic (emboic) acid, stearic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, ascorbic acid, glucoheptonic acid, glucuronic acid, lactic acid, lactobioic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, histidine, arginine, lysine, benethamine, N-methyl-glucamine, and ethanolamine. Other acids include dodecylsufuric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, and saccharin.
“Solvate” refers to the compound formed by the interaction of a solvent and fluoroquinolone antimicrobial, a metabolite, or salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.
By “therapeutically effective amount” or “pharmaceutically effective amount” is meant a fluoroquinolone anti-inflammatory agent, as disclosed for this invention, which has a therapeutic effect. The doses of fluoroquinolone anti-inflammatory agent which are useful in treatment are therapeutically effective amounts. Thus, as used herein, a therapeutically effective amount means those amounts of fluoroquinolone anti-inflammatory agent which produce the desired therapeutic effect as judged by clinical trial results and/or model animal anti-inflammatory studies. In particular embodiments, the fluoroquinolone anti-inflammatory agent are administered in a pre-determined dose, and thus a therapeutically effective amount would be an amount of the dose administered. This amount and the amount of the fluoroquinolone anti-inflammatory agent can be routinely determined by one of skill in the art, and will vary, depending on several factors, such as the particular inflammation involved, for example, the site of inflammation, the severity of inflammation. This amount can further depend upon the patient's height, weight, sex, age and medical history. For prophylactic treatments, a therapeutically effective amount is that amount which would be effective to prevent a particular inflammation.
A “therapeutic effect” relieves, to some extent, one or more of the symptoms of the inflammation, and includes curing an inflammation. “Curing” means that the symptoms of inflammation are eliminated. However, certain long-term or permanent effects of the inflammation may exist even after a cure is obtained (such as extensive tissue damage). As used herein, a “therapeutic effect” is defined as a statistically significant reduction in an inflammation, emergence of inflammation, or improvement in inflammation symptoms as measured by human clinical results or animal studies.
“Treat,” “treatment,” or “treating,” as used herein refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The term “prophylactic treatment” refers to treating a patient who is not yet having an inflammation, but who is susceptible to, or otherwise at risk of, a particular inflammation such that there is a reduced onset of an inflammation. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from an inflammation. Thus, in preferred embodiments, treating is the administration to a mammal (either for therapeutic or prophylactic purposes) of therapeutically effective amounts of a fluoroquinolone anti-inflammatory agent.
The term “dosing interval” refers to the time between administrations of the two sequential doses of a pharmaceutical's during multiple dosing regimens. For example, in the case of orally administered ciprofloxacin, which is administered twice daily (traditional regimen of 400 mg b.i.d) and orally administered levofloxacin, which is administered once a day (500 mg or 750 mg q.d.), the dosing intervals are 12 hours and 24 hours, respectively.
As used herein, the “peak period” of a pharmaceutical's in vivo concentration is defined as that time of the pharmaceutical dosing interval when the pharmaceutical concentration is not less than 50% of its maximum plasma or site-of-inflammation concentration. In some embodiments, “peak period” is used to describe an interval of anti-inflammatory dosing.
The “respirable delivered dose” is the amount of drug inhaled during the inspiratory phase of the breath simulator that is equal to or less than 5 microns using a simulator programmed to the European Standard pattern of 15 breaths per minute, with an inspiration to expiration ratio of 1:1.
As used herein “pulmonary concentration” can include the concentration of a substance in the lung of a subject, the concentration of a substance in the sputum of a subject, and/or the concentration of a substance in the bronchial alveoial lavage of a subject. As will be understood, “pulmonary concentration” can be measured by various methods.

Methods of Treatment or Prophylaxis

In some embodiments, a method is provided for treating an inflammation in an animal, specifically including in a mammal, by treating an animal suffering from such an inflammation with a fluoroquinolone anti-inflammatory agent formulated with a divalent or trivalent cation and having improved pulmonary availability. In some embodiments, fluoroquinolone anti-inflammatory agents may be administered following aerosol formation and inhalation. Thus, this method of treatment is especially appropriate for the treatment of pulmonary inflammations that are difficult to treat using an anti-inflammatory agent delivered parenterally due to the need for high parenteral dose levels (which can cause undesirable side effects), or due to lack of any clinically effective anti-inflammatory agents. In one such embodiment, this method may be used to administer a fluoroquinolone anti-inflammatory agent directly to the site of inflammation. Such a method may reduce systemic exposure and maximizes the amount of anti-inflammatory agent to the site of inflammation.
In some embodiments, the aerosol fluoroquinolone therapy may be administered as a treatment or prophylaxis in combination or alternating therapeutic sequence with other aerosol, oral or parenteral antibiotics. By non-limiting example this may include aerosol tobramycin and/or other aminoglycoside, aerosol aztreonam and/or other beta- or mono-bactam, carbapenems, aerosol ciprofloxacin and/or other fluoroquinolones, aerosol azithromycin and/or other macrolides or ketolides, tetracycline and/or other tetracyclines, quinupristin and/or other streptogramins, linezolid and/or other oxazolidinones, vancomycin and/or other glycopeptides, erythromycin, and chloramphenicol and/or other phenicols, and colisitin and/or other polymyxins.
In addition, compositions and methods provided herein can include the aerosol fluoroquinolone therapy administered as a treatment or prophylaxis in combination or alternating therapeutic sequence with an additional active agent. As discussed above, some such additional agents can include antibiotics. More additional agents can include bronchodilators, anticholinergics, glucocorticoids, eicosanoid inhibitors, and combinations thereof. Examples of bronchodilators include salbutamol, levosalbuterol, terbutaline, fenoterol, terbutlaine, pirbuterol, procaterol, bitolterol, rimiterol, carbuterol, tulobuterol, reproterol, salmeterol, formoterol, arformoterol, bambuterol, clenbuterol, indacterol, theophylline, roflumilast, cilomilast. Examples of anticholinergics include ipratropium, and tiotropium. Examples of glucocorticoids include prednisone, fluticasone, budesonide, mometasone, ciclesonide, and beclomethasone. Examples of eicosanoids include montelukast, pranlukast, zafirlukast, zileuton, ramatroban, and seratrodast. More additional agents can include pulmozyme, hypertonic saline, agents that restore chloride channel function in CF, inhaled beta-agonists, inhaled antimuscarinic agents, inhaled corticosteroids, and inhaled or oral phosphodiesterase inhibitors. More additional agents can include CFTR modulators, for example, VX-770, atluren, VX-809. More additional agents can include agents to restore airway surface liquid, for example, denufosol, mannitol, GS-9411, and SPI-8811 More additional agents can include anti-inflammatory agents, for example, ibuprofen, sildenafil, and simavastatin. More additional agent include anti-inflammatory agents. Examples of anti-inflammatory agents include steroidal and non-steriodal anti-inflammatory agent. Examples of steroidal anti-inflammatory agents include 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, chloroprednisone, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desciclesonide, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, any of their derivatives, analogues, and combinations thereof. Examples of nonsteriodal anti-inflammatory agents include COX inhibitors (COX-1 or COX nonspecific inhibitors) (e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam, meloxicam) and alkanones such as nabumetone) and selective COX-2 inhibitors (e.g., diaryl-substituted furanones such as rofecoxib; diaryl-substituted pyrazoles such as celecoxib; indole acetic acids such as etodolac and sulfonanilides such as nimesulide).

Pharmaceutical Compositions

For purposes of the method described herein, a fluoroquinolone anti-inflammatory agent formulated with a divalent or trivalent cation having improved pulmonary availability may be administered using an inhaler. In some embodiments, a fluoroquinolone anti-inflammatory agent disclosed herein is produced as a pharmaceutical composition suitable for aerosol formation, good taste, storage stability, and patient safety and tolerability. In some embodiments, the isoform content of the manufactured fluoroquinolone may be optimized for tolerability, anti-inflammatory activity and stability.
Formulations can include a divalent or trivalent cation. The divalent or trivalent cation can include, for example, magnesium, calcium, zinc, copper, aluminum, and iron. In some embodiments, the solution comprises magnesium chloride, magnesium sulfate, zinc chloride, or copper chloride. In some embodiments, the divalent or trivalent cation concentration can be from about 25 mM to about 400 mM, from about 50 mM to about 400 mM, from about 100 mM to about 300 mM, from about 100 mM to about 250 mM, from about 125 mM to about 250 mM, from about 150 mM to about 250 mM, from about 175 mM to about 225 mM, from about 180 mM to about 220 mM, and from about 190 mM to about 210 mM. In some embodiments, the chloride concentration can be from about 25 mM to about 800 mM, from about 50 mM to about 400 mM, from about 100 mM to about 300 mM, from about 100 mM to about 250 mM, from about 125 mM to about 250 mM, from about 150 mM to about 250 mM, from about 175 mM to about 225 mM, from about 180 mM to about 220 mM, and from about 190 mM to about 210 mM. In some embodiments, the magnesium chloride, magnesium sulfate, zinc chloride, or copper chloride can have a concentration from about 5% to about 25%, from about 10% to about 20%, and from about 15% to about 20%. In some embodiments, the ratio of fluoroquinolone to divalent or trivalent cation can be 1:1 to 2:1 or 1:1 to 1:2.
Non-limiting fluoroquinolones for use as described herein include levofloxacin, ofloxacin, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, lomefloxacin, moxifloxacin, norfloxacin, pefloxacin, sparfloxacin, garenoxacin, sitafloxacin, and DX-619.
The formulation can have a fluoroquinolone concentration, for example, levofloxacin or ofloxacin, greater than about 50 mg/ml, about 60 mg/ml, about 70 mg/ml, about 80 mg/ml, about 90 mg/ml, about 100 mg/ml, about 110 mg/ml, about 120 mg/ml, about 130 mg/ml, about 140 mg/ml, about 150 mg/ml, about 160 mg/ml, about 170 mg/ml, about 180 mg/ml, about 190 mg/ml, and about 200 mg/ml. In some embodiments, the formulation can have a fluoroquinolone concentration, for example, levofloxacin or ofloxacin, from about 50 mg/ml to about 200 mg/ml, from about 75 mg/ml to about 150 mg/ml, from about 80 mg/ml to about 125 mg/ml, from about 80 mg/ml to about 120 mg/ml, from about 90 mg/ml to about 125 mg/ml, from about 90 mg/ml to about 120 mg/ml, and from about 90 mg/ml to about 110 mg/ml.
The formulation can have an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg, from about 325 mOsmol/kg to about 450 mOsmol/kg, from about 350 mOsmol/kg to about 425 mOsmol/kg, and from about 350 mOsmol/kg to about 400 mOsmol/kg. In some embodiments, the osmolality of the formulation is greater than about 300 mOsmol/kg, about 325 mOsmol/kg, about 350 mOsmol/kg, about 375 mOsmol/kg, about 400 mOsmol/kg, about 425 mOsmol/kg, about 450 mOsmol/kg, about 475 mOsmol/kg, and about 500 mOsmol/kg.
The formulation can have a pH from about 4.5 to about 8.5, from about 5.0 to about 8.0, from about 5.0 to about 7.0, from about 5.0 to about 6.5, from about 5.5 to about 6.5, and from 6.0 to about 6.5.
The formulation can comprise a conventional pharmaceutical carrier, excipient or the like (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like), or auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like). In some embodiments, the formulation can lack a conventional pharmaceutical carrier, excipient or the like. Some embodiments include a formulation lacking lactose. Some embodiments comprise lactose at a concentration less than about 10%, 5%, 1%, or 0.1%. In some embodiments, the formulation can consist essentially of levofloxacin or ofloxacin and a divalent or trivalent cation.
In some embodiments, a formulation can comprise a levofloxacin concentration between about 75 mg/ml to about 150 mg/ml, a magnesium chloride concentration between about 150 mM to about 250 mM, a pH between about 5 to about 7; an osmolality of between about 300 mOsmol/kg to about 500 mOsmol/kg, and lacks lactose.
In some embodiments, a formulation comprises a levofloxacin concentration about 100 mg/ml, a magnesium chloride concentration about 200 mM, a pH about 6.2 an osmolality about 383 mOsmol/kg, and lacks lactose. In some embodiments, a formulation consists essentially of a levofloxacin concentration about 100 mg/ml, a magnesium chloride concentration about 200 mM, a pH about 6.2 an osmolality about 383 mOsmol/kg, and lacks lactose. In some embodiments, a formulation consists of a levofloxacin concentration about 100 mg/ml, a magnesium chloride concentration about 200 mM, a pH about 6.2 an osmolality about 383 mOsmol/kg, and lacks lactose.

Administration

The fluoroquinolone anti-inflammatory agents formulated with divalent or trivalent cations and having improved pulmonary availability may be administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described. The amount of active compound administered will, of course, be dependent on the subject and disease state being treated, the severity of the inflammation, the manner and schedule of administration and the judgment of the prescribing physician; for example, a likely dose range for aerosol administration of levofloxacin would be about 20 to 300 mg per day, the active agents being selected for longer or shorter pulmonary half-lives, respectively. In some embodiments, a likely dose range for aerosol administration of levofloxacin would be about 20 to 300 mg BID (twice daily).
Administration of the fluoroquinolone antimicrobial agents disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, aerosol inhalation. Methods, devices and compositions for delivery are described in U.S. Patent Application Publication No. 2006/0276,483, incorporated by reference in its entirety.
Pharmaceutically acceptable compositions include solid, semi-solid, liquid and aerosol dosage forms, such as, for example, powders, liquids, suspensions, complexations, liposomes, particulates, or the like. Preferably, the compositions are provided in unit dosage forms suitable for single administration of a precise dose.
The fluoroquinolone anti-inflammatory agent can be administered either alone or in some alternatives, in combination with a conventional pharmaceutical carrier, excipient or the like (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like). Generally, depending on the intended mode of administration, the pharmaceutical formulation will contain about 0.005% to 95%, preferably about 0.5% to 50% by weight of a compound of the invention. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.
In one preferred embodiment, the compositions will take the form of a unit dosage form such as vial containing a liquid, solid to be suspended, dry powder, lyophilate, or other composition and thus the composition may contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like.
Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Solutions to be aerosolized can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to aerosol production and inhalation. The percentage of active compound contained in such aerosol compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 90% in solution are employable, and will be higher if the composition is a solid, which will be subsequently diluted to the above percentages. In some embodiments, the composition will comprise 1.0%-50.0% of the active agent in solution.
Compositions described herein can be administered with a frequency of about 1, 2, 3, 4, or more times daily, 1, 2, 3, 4, 5, 6, 7 or more times weekly, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times monthly. In particular embodiments, the compositions are administered twice daily.
Aerosol delivery
For pulmonary administration, the upper airways are avoided in favor of the middle and lower airways. Pulmonary drug delivery may be accomplished by inhalation of an aerosol through the mouth and throat. Particles having a mass median aerodynamic diameter (MMAD) of greater than about 5 microns generally do not reach the lung; instead, they tend to impact the back of the throat and are swallowed and possibly orally absorbed. Particles having diameters of about 2 to about 5 microns are small enough to reach the upper- to mid-pulmonary region (conducting airways), but are too large to reach the alveoli. Smaller particles, i.e., about 0.5 to about 2 microns, are capable of reaching the alveolar region. Particles having diameters smaller than about 0.5 microns can also be deposited in the alveolar region by sedimentation, although very small particles may be exhaled.
In one embodiment, a nebulizer is selected on the basis of allowing the formation of an aerosol of a fluoroquinolone anti-inflammatory agent disclosed herein having an mMAD predominantly between about 2 to about 5 microns. In one embodiment, the delivered amount of fluoroquinolone anti-inflammatory agent provides a therapeutic effect for respiratory infections. The nebulizer can deliver an aerosol comprising a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns, a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns, and a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns. In some embodiments, the aerosol can be produced a jet nebulizer. In some embodiments, the aerosol can be produced using a vibrating mesh nebulizer. An example of a vibrating mesh nebulizer includes the PART E-FLOW® nebulizer. More examples of nebulizers are provided in U.S. Pat. Nos. 4,268,460; 4,253,468; 4,046,146; 3,826,255; 4,649,911; 4,510,929; 4,624,251; 5,164,740; 5,586,550; 5,758,637; 6,644,304; 6,338,443; 5,906,202; 5,934,272; 5,960,792; 5,971,951; 6,070,575; 6,192,876; 6,230,706; 6,349,719; 6,367,470; 6,543,442; 6,584,971; 6,601,581; 4,263,907; 5,709,202; 5,823,179; 6,192,876; 6,644,304; 5,549,102; 6,083,922; 6,161,536; 6,264,922; 6,557,549; and 6,612,303 all of which are hereby incorporated by reference in their entireties. More commercial examples of nebulizers that can be used with the formulations described herein include Respirgard II®, Aeroneb®, Aeroneb® Pro, and Aeroneb® Go produced by Aerogen; AERx® and AERx Essence™ produced by Aradigm; Porta-Neb®, Freeway Freedom™, Sidestream, Ventstream and I-neb produced by Respironics, Inc.; and PAM LC-Plus®, PAM LC-Star®, produced by PAM, GmbH. By further non-limiting example, U.S. Pat. No. 6,196,219, is hereby incorporated by reference in its entirety.
The amount of levofloxacin or ofloxacin that can be administered to the lungs can include at least about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 125 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, and about 800 mg.
The aerosol can be administered to the lungs in less than about 120 minutes, about 100 minutes, about 90 minutes, about 80 minutes, about 70 minutes, about 60 minutes, about 20 minutes, about 10 minutes, about 5 minutes, about 4 minutes, about 3 minutes, about 2 minutes, and about 1 minute.

Indications

Some embodiments of the methods and compositions described herein relate to treating particular disorders and diseases associated inflammation. In particular embodiments, the inflammation can be acute or chronic inflammation of the lung or the upper airway. As used herein “pulmonary inflammation” can refer to acute or chronic inflammation of at least a portion of the respiratory tract, such as the lungs and upper airway. Examples of such disorders and diseases associated with pulmonary inflammation can include asthma, cystic fibrosis, pulmonary fibrosis, chronic bronchitis, bronchiectasis, chronic granulomatous disease, sinusitis, chronic obstructive pulmonary disease, and pneumonia.
Some embodiments include methods to achieve a reduction in pulmonary inflammation. A reduction can include reducing the signs and symptoms of a pulmonary inflammation. In some embodiments, methods include achieving a reduction in the levels of pro-inflammatory cytokines in the lungs. A reduction in the levels of pro-inflammatory cytokines in the lungs can be measured by various methods, such as a reduction in the levels of pro-inflammatory cytokines in sputum and/or BAL. In some embodiments, methods include achieving a reduction in the levels of IL-1β, IL-6, and IL-8 in the lungs.

EXAMPLES

Example 1

In Vitro Activity of Levofloxacin, Ciprofloxacin and Moxifloxacin at Low Concentrations on IL-6 and IL-8 Production

NL20 cells and HBE135 cells are immortalized human airway epithelial cells that retain certain features of airway epithelium and have been extensively used to characterize immunomodulatory effects of other antibiotics (Blau H, et al. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 2007; 292:L343-352; and Donnarumma G, et al. Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide. Peptides 2007; 28:2286-2292, incorporated by reference in their entireties). IL-6 and IL-8 production in the NL20 and HBE135 cells was induced by adding TNFα or Lipopolysaccharide (LPS) from Pseudomonas aeruginosa, respectively. The effect of antibiotics on cytokine levels was assessed by ELISA assay.
NL20 cells were maintained in Ham's F12 medium with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 5 μg/ml insulin, 10 ng/ml epidermal growth factor, 1 μg/ml transferrin, 500 ng/ml hydrocortisone and 4% FBS. HBE135 cells were routinely grown in keratinocyte-serum free medium with 5 ng/ml of human recombinant EGF and 0.05 mg/ml of bovine pituitary extract (Invitrogen, San Diego, Calif.) supplemented with 5 μg/ml insulin and 500 ng/ml hydrocortisone.
NL20 cells were seeded on 24-well tissue culture plates at 2×10⁴cell/ml. The day after seeding, cells received normal growth medium without serum for an additional 24 h. The same serum-free media was used for all subsequent treatments of NL20 cells. IL-6 and IL-8 production in NL20 monolayers was induced by treatment with 10 ng/ml of TNFα. HBE135 Cells were aliquoted into 24-well tissue culture plates at 1×10⁵cells/ml and were used for cytokine production experiments approximately 24 hours after plating without additional media changes. IL-6 and IL-8 production in HBE135 cells was induced by treatment with 5 μg/ml of LPS from P. aeruginosa. After 48 h, cell medium was collected, clarified and the amount of IL-6 and IL-8 released into the medium was quantified using QuantiGlo chemiluminescent ELISA kits (R&D Systems, Minneapolis, Minn.). To test the effect of antibiotics on IL-6 and IL-8 secretion, antibiotics were added to culture media along with LPS or TNF-α and processed as described above.
TNF-α induced a several-fold increase in IL-6 and IL-8 production in NL20 cells (FIGS. 1A and 1B). LPS induced an increase in the level of IL-8 in HBE135 cells (FIG. 2B). In NL20 cells treated with 10 μg/ml and 30 μg/ml levofloxacin, moxifloxacin or ciprofloxacin, IL-8 levels were reduced by approximately 20-30% (FIGS. 1A and 1B). No significant change in IL-6 levels was observed in cells treated with levofloxacin or ciprofloxacin. However, in NL20 cells treated with 30 μg/ml ciprofloxacin, an increase in IL-6 levels was observed. FIGS. 2A and 2B show the levels of IL-6 and IL-8 in cells. In HBE135 cells treated with 10 μg/ml and 30 μg/ml levofloxacin, moxifloxacin or ciprofloxacin. This experiment shows that low concentrations of levofloxacin can reduce the levels of IL-8 in HBE135 cells stimulated with LPS.

Example 2

In Vitro Ccytotoxicity of Levofloxacin, Ciprofloxacin and Moxifloxacin

The cytotoxicity of levofloxacin, moxifloxacin and ciprofloxacin on NL20 and HBE135 cell lines were measured using an Alamar Blue assay. After 48 hour incubation with the antibiotic, cells were incubated in fresh growth media containing 5% Alamar Blue dye and fluorescence was recorded at 0 h and 4 h to assess antibiotic cytotoxicity. Higher levofloxacin concentrations were less cytotoxic to either NL20 or HBE135 cells compared to moxifloxacin and ciprofloxacin (FIGS. 3A and 3B). Moxifloxacin and ciprofloxacin were significantly cytotoxic to NL20 cells at 300 μg/ml.

Example 3

In Vitro Activity of Levofloxacin on IL-6 and IL-8 Production

NL20 cells induced with TNFα and HBE135 cells induced with LPS were treated with 300 μg/ml levofloxacin or 300 μg/ml levofloxacin formulated with MgCl₂. An approximate 10-fold and 5-fold reduction in IL-6 and IL-8 levels, respectively, was observed in NL20 cells treated with 300 μg/ml levofloxacin or 300 μg/ml levofloxacin formulated with MgCl₂. (FIGS. 4A and 4B). In addition, reductions in IL-6 and IL-8 levels were observed in HBE cells treated with 300 μg/ml levofloxacin or 300 μg/ml levofloxacin formulated with MgCl₂(FIGS. 4C and 4D). Levofloxacin and levofloxacin formulated with MgCl₂had similar activity in vitro.

Example 5

In Vitro Activity of Levofloxacin and Tobramycin

TNFα-induced NL20 cells and LPS-induced HBE135 cells were treated with 10-300 μg/ml levofloxacin, or tobramycin. No significant changes in cell viability in cytotoxicity assays were observed between any treatment (data not shown).
In NL20 cells treated with 10 ng/ml TNFα, an increase in IL-6 production from 3.4±0.2 pg/ml to 40.3±2.3 pg/ml was observed (FIG. 5A). IL-8 production increased from 3.3±0.2 pg/ml to 197.3±28.9 pg/ml (FIG. 5B). Incubation of NL20 cells with 5 μg/ml LPS did not produce significant increases in either IL-6 or IL-8 production (data not shown). The addition of 10 μg/ml or 30 μg/ml levofloxacin did not significantly change the level of IL-6 and IL-8 produced by NL20 cells. However, 100 μg/ml and 300 μg/ml levofloxacin resulted in 2- to 4-fold reductions in IL-6 levels, respectively (p<0.005) (FIG. 5A). Levels of IL-8 decreased by 50% and 60% in NL20 cells treated with 100 μg/ml and 300 μg/ml levofloxacin, respectively (p<0.005) (FIG. 5B). 10 μg/ml to 100 μg/ml tobramycin did not significantly affect production of IL-6 or IL-8 (FIGS. 5A and 5B). However, 300 μg/ml tobramycin produced an increase in IL-6 production (FIG. 5A). Thus, levofloxacin demonstrates an ability to reduce pro-inflammatory cytokine production in vitro in NL20 cells
Incubation of HBE135 cells with 5 μg/ml LPS increased IL-6 production from 46.1±6.4 pg/ml to 86.3±6.4 pg/ml and IL-8 production from 280.7±54.9 pg/ml to 541.9±54.8 pg/ml. Incubation of HBE135 cells with 10 or 30 μg/ml levofloxacin and LPS cells did not significantly change IL-6 and IL-8 levels. However, 100 μg/ml and 300 μg/ml levofloxacin resulted in a 45% and 40% decrease in IL-6 levels, respectively (FIG. 6). Levels of IL-8 decreased by 30% and 20% in HBE135 cells treated with 100 μg/ml and 300 μg/ml levofloxacin, respectively (FIG. 6). Incubation of cells with 10 μg/ml, 30 μg/ml, or 100 μg/ml tobramycin did not affect the levels of IL-6, while 300 μg/ml of tobramycin increased levels of IL-6 by 30%. Treatment with 30 μg/ml to 300 μg/ml tobramycin increased IL-8 production by 20% to 30% (p<0.05).
These in vitro studies demonstrated that levofloxacin can induce a dose-related reduction in the production of the pro-inflammatory cytokines, IL-6 and IL-8, in cultured human lung epithelial cell lines. 300 μg/ml levofloxacin reduced levels of IL-6 by 4-fold and IL-8 by 2-fold (p<0.05); in contrast, tobramycin increased IL-6 levels by 50%, but had no effect on IL-8. These findings suggest that high concentrations of levofloxacin obtained in pulmonary tissues following treatment with aerosol levofloxacin formulated with MgCl₂will provide antinflammatory benefits in patients with chronic pulmonary infections.

Example 6

In Vitro Activity of Levofloxacin in Human Monocytic Cells

The human monocyte cell line, THP-1 is an established in vitro model of human monocytic cells and is capable to secrete a greater variety of cytokines compared to NL20 and HBE135 cells. THP-1 cells were cultured in RPMI-1640 medium with 10%FBS, 0.05 mM 2-mecraptoethanol. THP-1 cells were seeded on 24-well tissue culture plates at 1×10⁶cells/ml in growth media without serum. The following day, 100 ng/ml LPS from P. aeruginosa and antibiotics were added and cells incubated for 24 hours before media collection to assess cytokine production. Quantification of IL-6, IL-8, IL-1β and TNFα production was performed as described above for NL20 cells.
Stimulation of THP-1 with 10 ng/ml of LPS increased IL-1β, TNFα, IL-6 and IL-8 levels by 60-, 200-, 30- and 600-fold, respectively (FIGS. 7A, 7B, 7C, and 7D). Co-incubation of LPS and at 100 μg/ml and 300 μg/ml levofloxacin resulted in a 40% and 70% decrease in IL-1β levels, respectively (FIG. 7A). 300 μg/ml levofloxacin increased TNFα production (FIG. 7B). Incubation with increased concentrations of levofloxacin caused dose-dependent decrease of IL-6 production, with 300 μg/ml levofloxacin reducing IL-6 levels by five-fold (FIG. 7C). Levels of IL-8 were significantly decreased by 100 μg/ml and 300 μg/ml levofloxacin (FIG. 7D).

Example 7

In Vitro Cctivity of Levofloxacin on IL-8 mRNA Expression

The human monocyte cell line, THP-1 is an established in vitro model of human monocytic cells and is capable to secrete a greater variety of cytokines compared to NL20 and HBE135 cells. IL-8 mRNA expression in NL20 monolayers was induced by treatment with 10 ng/ml TNFα. Levofloxacin was added simultaneously with TNFα. After 24 h incubation, the cell monolayer was washed with PBS, total cellular RNA was prepared and reverse transcription was performed using a human IL-8 specific primer and the “Cells-to-cDNA” kit from Ambion (Austin, Tex.). cDNA was subjected to real-time PCR analysis using PowerSYBR Green PCR master mix and a GeneAmp 5700 Instrument (Applied Biosystems; Warrington, UK). All data were normalized to the housekeeping gene β-actin. Stimulation of NL-20 cells with TNFα, produced a statistically significant (p<0.005) 20-fold increase in IL-8 mRNA levels (FIG. 8). This increase correlates with the increased levels of IL-8 protein induced by TNFα. Addition of 100 μg/ml and 300 μg/ml levofloxacin had no significant effect on the level of IL-8 mRNA expression (FIG. 4). These results suggest that levofloxacin reduces levels of the IL-8 secreted protein by modulating processes that include protein translation and/or protein secretion.

Example 8

In Vitro Activity of Levofloxacin on NFkB Activity

NFkB and AP-1 are important regulators in the transcriptional activity of some pro-inflammatory cytokines. This example relates to the effect of levofloxacin on the transcriptional regulatory activity of NFkB.
The human monocyte cell line, THP-1 is an established in vitro model of human monocytic cells and is capable to secrete a greater variety of cytokines compared to NL20 and HBE135 cells. Cells were seeded on 96-well plate at 3×10⁴cells/well and transfected the following day with a pMetLuc-NFkB reporter plasmid (Clontech) encoding a secreted luciferase protein under the control of a NFkB-regulated promoter. To normalize transfection efficiency, cells were cotransfected with a pSEAP-Control plasmid (Clontech) encoding a secreted alkaline phosphatase under the control of a strong constitutive promoter. 24 hours after transfection, media was replaced with fresh serum-free media containing 10 ng/ml TNF-α and levofloxacin. 8 hours after incubation, cell supernates were collected, and luciferase and alkaline phosphatase activities were measured using the “Ready-to-Glow Dual Secreted Reporter assay” (Clontech, Mountain View, Calif.). Cells transfected with the reporter plasmid encoding luciferase gene under control of NFkB transcription factor produced a low basal level of luciferase activity. Stimulation with TNFα, a known activator of the NFkB pathway, resulted in an almost 20-fold increase in promoter activity (FIG. 9). Addition of 100 μg/ml and 300 μg/ml levofloxacin did not produce a significant effect on the level of reporter gene activity. This suggests that levofloxacin did not affect TNFα-stimulated transcriptional activity of NFkB.

Example 9

In Vivo Anti-Inflammatory Activity of Levofloxacin Formulated with MgCl₂

Mice (n=4) were injected with 50 μg LPS by an intraperitoneal route. Thirty minutes after LPS treatment, mice were treated using a microspray aerosol device (PennCentury, Philadelphia) with 60 mg/kg saline control, levofloxacin formulated with MgCl₂, or tobramycin. Mice were sacrificed 6 hours after aerosolized treatment, and bronchoalveolar (BAL) fluid was collected by lavage with 1 ml saline. IL-6 and MIP-2 (murine homolog of human IL-8) levels were determined by ELISA.
Treatments with saline, levofloxacin formulated with MgCl₂, and tobramycin resulted in mean MIP-2 levels of 515 pg/ml, 233 pg/ml, and 502 pg/ml, respectively (FIG. 10A). Treatment with levofloxacin formulated with MgCl₂resulted in more than a 2-fold reduction in MIP-2 levels relative to the saline control. Moreover, the reduction was significantly greater than both saline and tobramycin treated mice (p<0.05). A similar trend was observed in IL-6 levels (FIG. 10B). Treatment with levofloxacin produced IL-6 levels more than 2-fold lower than IL-6 levels in the saline control (p<0.05). Treatment with tobramycin resulted in an increase in IL-6 levels compared to the saline control. This in vivo data is consistent with the in vitro data of Example 5, where treatment with levofloxacin decreased levels of IL-6 and IL-8, while tobramycin had no significant effect on IL-8 levels and a trend towards increasing IL-6 levels.
This in vivo study shows that treatment with high concentrations of levofloxacin formulated with MgCl₂can reduce pro-inflammatory cytokines that include IL-6 and IL-8. Accordingly, these findings suggest that in addition to potent antibacterial effects, high concentrations of levofloxacin may have anti-inflammatory benefits in patients susceptible to acute and chronic inflammations, for example patients with CF and COPD.

Example 10

Anti-Inflammatory Activity of Levofloxacin Formulated with MgCl₂in CF Patients

CF patients having acute or chronic pulmonary inflammation are administered aerosol levofloxacin formulated with MgCl₂. After treatment, a reduction in the acute inflammation is observed. A reduction in the levels of pro-inflammatory cytokines is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the lungs is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the sputum and/or BAL is observed.

Example 11

Anti-Inflammatory Activity of Levofloxacin Formulated with MgCl₂in COPD Patients

COPD patients having acute or chronic pulmonary inflammation are administered aerosol levofloxacin formulated with MgCl₂. After treatment, a reduction in the acute inflammation is observed. A reduction in the levels of pro-inflammatory cytokines is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the lungs is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the sputum and/or BAL is observed.

Example 12

Anti-Inflammatory Activity of Levofloxacin Formulated with MgCl₂in Chronic Bronchitis Patients

Chronic bronchitis patients having acute or chronic pulmonary inflammation are administered aerosol levofloxacin formulated with MgCl₂. After treatment, a reduction in the acute inflammation is observed. A reduction in the levels of pro-inflammatory cytokines is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the lungs is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the sputum and/or BAL is observed.

Example 13

Anti-Inflammatory Activity of Levofloxacin Formulated with MgCl₂in Bronchiectasis Patients

Bronchiectasis patients having acute or chronic pulmonary inflammation are administered aerosol levofloxacin formulated with MgCl₂. After treatment, a reduction in the acute inflammation is observed. A reduction in the levels of pro-inflammatory cytokines is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the lungs is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the sputum and/or BAL is observed.

Example 14

Anti-Inflammatory Activity of Levofloxacin Formulated with MgCl₂in Non-CF Bronchiectasis Patients

Non-CF bronchiectasis patients having acute or chronic pulmonary inflammation are administered aerosol levofloxacin formulated with MgCl₂. After treatment, a reduction in the acute inflammation is observed. A reduction in the levels of pro-inflammatory cytokines is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the lungs is observed. A reduction in the levels of IL-1β, IL-6, and IL-8 in the sputum and/or BAL is observed.
To the extent publications and patents or patent applications incorporated by reference herein contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to a person of ordinary skill in the art, and are not to be limited to a special or customized meaning unless expressly so defined herein.
Terms and phrases used in this application, and variations thereof, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as ‘known’, ‘normal’, ‘standard’, and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like ‘preferably,’ preferred,‘desired,’ or ‘desirable,’ and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the invention, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the invention. Likewise, a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise. Similarly, a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise. In addition, as used in this application, the articles ‘a’ and ‘an’ should be construed as referring to one or more than one (i.e., to at least one) of the grammatical objects of the article. By way of example, ‘an element’ means one element or more than one element.
The presence in some instances of broadening words and phrases such as ‘one or more’, ‘at least’, ‘but not limited to’, or other like phrases shall not be read to mean that the narrower case is intended or required in instances where such broadening phrases may be absent.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term ‘about.’ Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
Furthermore, although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it is apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather to also cover all modification and alternatives coming with the true scope and spirit of the invention.

Claims

What is claimed is:

1. A method for treating a pulmonary inflammation in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation.

2. The method of claim 1, wherein the pulmonary inflammation is associated with at least one disorder selected from asthma, cystic fibrosis (CF), pulmonary fibrosis, chronic bronchitis (CB), bronchiectasis, chronic granulomatous disease, sinusitis, chronic obstructive pulmonary disease (COPD), or pneumonia.

3. The method of claim 1, wherein the solution consists essentially of levofloxacin or ofloxacin and the divalent or trivalent cation.

4. The method of claim 1, wherein the solution comprises chloride.

5. The method of claim 1, wherein the solution comprises no lactose.

6. The method of claim 1, wherein the solution comprises a divalent or trivalent cation concentration from about 100 mM to about 300 mM, and a levofloxacin or ofloxacin concentration from between about 75 mg/ml to about 150 mg/ml.

7. The method of claim 1, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from between about 90 mg/ml to about 125 mg/ml.

8. The method of claim 1, wherein the solution comprises an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg, and a pH from about 5 to about 8.

9. The method of claim 1, wherein the solution comprises an osmolality from about 350 mOsmol/kg to about 425 mOsmol/kg, and a pH from about 5 to about 6.5.

10. The method of claim 1, wherein the solution comprises a pH from about 5.5 to about 6.5.

11. The method of claim 1, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum, and iron.

12. The method of claim 1, wherein the solution comprises magnesium chloride.

13. The method of claim 1, wherein the solution comprises a levofloxacin or ofloxacin concentration between about 90 mg/ml to about 110 mg/ml, a magnesium chloride concentration between about 175 mM to about 225 mM, a pH between about 5 to about 7; an osmolarity of between about 300 mOsmol/kg to about 500 mOsmol/kg, and lacks lactose.

14. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns.

15. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns.

16. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns.

17. The method of claim 1, comprising producing the aerosol with a vibrating mesh nebulizer.

18. The method of claim 17, wherein the vibrating mesh nebulizer is a PART E-FLOW® nebulizer.

19. The method of claim 1, wherein at least about 20 mg of levofloxacin or ofloxacin is administered to the lung.

20. The method of claim 1, wherein at least about 100 mg of levofloxacin or ofloxacin is administered to the lung.

21. The method of claim 1, wherein at least about 125 mg of levofloxacin or ofloxacin is administered to the lung.

22. The method of claim 1, wherein at least about 150 mg of levofloxacin or ofloxacin is administered to the lung.

23. The method of claim 1, wherein the aerosol is administered to the lung in less than about 10 minutes.

24. The method of claim 1, wherein the aerosol is administered to the lung in less than about 5 minutes.

25. The method of claim 1, wherein the aerosol is administered to the lung in less than about 3 minutes.

26. The method of claim 1, wherein the aerosol is administered to the lung in less than about 2 minutes.

27. The method of claim 1, comprising administering the aerosol once daily.

28. The method of claim 1, comprising administering the aerosol twice daily.

29. The method of claim 1, further comprising co-administering an additional active agent selected from the group consisting of anti-inflammatory agent, antibiotic, bronchodilator, anticholinergic, glucocorticoid, eicosanoid inhibitor, and combinations thereof.

30. The method of claim 29, wherein co-administering comprises inhaling the additional active agent.

31. The method of claim 29, wherein the antibiotic is selected from the group consisting of tobramycin, aztreonam, ciprofloxacin, azithromycin, erythromycin tetracycline, quinupristin, linezolid, vancomycin, and chloramphenicol, colisitin and combinations thereof.

32. The method of claim 29, wherein the bronchodilator is selected from the group consisting of salbutamol, levosalbuterol, terbutaline, fenoterol, terbutlaine, pirbuterol, procaterol, bitolterol, rimiterol, carbuterol, tulobuterol, reproterol, salmeterol, formoterol, arformoterol, bambuterol, clenbuterol, indacterol, theophylline, roflumilast, cilomilast, and combinations thereof.

33. The method of claim 29, wherein the anticholinergic is selected from the group consisting of ipratropium, tiotropium, and combinations thereof.

34. The method of claim 29, wherein the glucocorticoid is selected from the group consisting of prednisone, fluticasone, budesonide, mometasone, ciclesonide, beclomethasone, and combinations thereof.

35. The method of claim 29, wherein the eicosanoid is selected from the group consisting of montelukast, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, and combinations thereof.

36. A method for treating a pulmonary inflammation in a subject, wherein the pulmonary inflammation is induced by one or more pro-inflammatory cytokines, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of said cytokine by at least 10%.

37. The method of claim 36, wherein the pulmonary concentration of said cytokine is reduced by at least 20%.

38. The method of claim 36, wherein the pulmonary concentration of said cytokine is reduced by at least 40%.

39. The method of claim 36, wherein the pulmonary concentration of said cytokine is reduced by at least 60%.

40. The method of claim 36, wherein the pulmonary concentration of said cytokine is reduced by at least 80%.

41. A method for treating a pulmonary inflammation in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of one or more pro-inflammatory cytokines selected from IL-1β, IL-6 and IL-8, whereby the pulmonary inflammation is reduced or suppressed.

42. The method of claim 41, wherein the cytokine comprises IL-1β.

43. The method of claim 41, wherein the cytokine comprises IL-6.

44. The method of claim 41, wherein the cytokine comprises IL-8.

45. A method for treating a pulmonary inflammation in a subject, wherein the pulmonary inflammation is induced by one or more mediators selected from TNFα and LPS, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation.

46. A method for reducing the pulmonary concentration of a pro-inflammatory cytokine in a subject, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, whereby the pulmonary concentration of said cytokine is reduced.

47. The method of claim 46, wherein the cytokine comprises IL-1β.

48. The method of claim 46, wherein the cytokine comprises IL-6.

49. The method of claim 46, wherein the cytokine comprises IL-8.